Skip to content

Breakthrough Therapies for Skin Diseases™

Alphyn Doses First Patient in Phase 2b Clinical Trial of Zabalafin Hydrogel for Atopic Dermatitis

Alphyn
Breakthrough Therapies for Skin Diseases
Alphyn
  • About
    • What We Do
    • Leadership & Board
    • Science Advisory
  • Platform
    • Zabalafin Platform
  • Pipeline
    • Atopic Dermatitis
    • Epidermolysis Bullosa
  • News
    • Press Releases
    • In the News
    • Clinical Presentations
    • Events
  • Contact Us
  • About
    • What We Do
    • Leadership & Board
    • Science Advisory
  • Platform
    • Zabalafin Platform
  • Pipeline
    • Atopic Dermatitis
    • Epidermolysis Bullosa
  • News
    • Press Releases
    • In the News
    • Clinical Presentations
    • Events
  • Contact Us

Daily Archives: July 17, 2023

You are here:
  1. Home
  2. 2023
  3. July
  4. 17

Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria

NewsBy adminJuly 17, 2023

Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 17, 2023 80% of patients achieved an itch score improvement of 4 points or more. 90% of patients achieved EASI 50 and 44% achieved EASI 75. Read the Healio article here. CONTACTS   Corporate: Neal…

Copyright 2025, Alphyn Biologics, Inc. All rights reserved. | Website Design by ABWeb Beacon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to Top